[go: up one dir, main page]

MX2018010291A - Vacunas novedosas contra el virus de zika. - Google Patents

Vacunas novedosas contra el virus de zika.

Info

Publication number
MX2018010291A
MX2018010291A MX2018010291A MX2018010291A MX2018010291A MX 2018010291 A MX2018010291 A MX 2018010291A MX 2018010291 A MX2018010291 A MX 2018010291A MX 2018010291 A MX2018010291 A MX 2018010291A MX 2018010291 A MX2018010291 A MX 2018010291A
Authority
MX
Mexico
Prior art keywords
mammal
zika
zika virus
immune response
plasmid dna
Prior art date
Application number
MX2018010291A
Other languages
English (en)
Inventor
Muthumani Karuppiah
Weiner David
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2018010291A publication Critical patent/MX2018010291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un aspecto de la presente invención se refiere a construcciones de ácido nucleico capaces de expresar un antígeno de Zika que provoca una respuesta inmunitaria en un mamífero contra el virus de Zika, y métodos de usos de estas. Además, hay vacunas de plásmidos de ADN capaces de generar una respuesta inmunitaria contra un virus de Zika en un mamífero, que comprenden un plásmido de ADN y un excipiente farmacéuticamente aceptable y métodos de uso de estas. El plásmido de ADN es capaz de expresar un antígeno de Zika en una célula del mamífero en una cantidad efectiva para provocar una respuesta inmunitaria en el mamífero que tenga reactividad cruzada frente a todas las cepas de Zika.
MX2018010291A 2016-02-25 2017-02-24 Vacunas novedosas contra el virus de zika. MX2018010291A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662300030P 2016-02-25 2016-02-25
US201662305183P 2016-03-08 2016-03-08
US201662396742P 2016-09-19 2016-09-19
US201662417100P 2016-11-03 2016-11-03
US201762462249P 2017-02-22 2017-02-22
PCT/US2017/019407 WO2017147458A1 (en) 2016-02-25 2017-02-24 Novel vaccines against zika virus

Publications (1)

Publication Number Publication Date
MX2018010291A true MX2018010291A (es) 2019-06-06

Family

ID=59685658

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018010291A MX2018010291A (es) 2016-02-25 2017-02-24 Vacunas novedosas contra el virus de zika.
MX2023006203A MX2023006203A (es) 2016-02-25 2018-08-24 Vacunas novedosas contra el virus de zika.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023006203A MX2023006203A (es) 2016-02-25 2018-08-24 Vacunas novedosas contra el virus de zika.

Country Status (10)

Country Link
US (2) US11648303B2 (es)
EP (1) EP3419660A4 (es)
JP (3) JP7012365B2 (es)
KR (1) KR20190003471A (es)
CN (2) CN109152826B (es)
AU (3) AU2017222644B2 (es)
BR (1) BR112018017307A2 (es)
CA (1) CA3015792A1 (es)
MX (2) MX2018010291A (es)
WO (1) WO2017147458A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017015463A2 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
MX2018010291A (es) 2016-02-25 2019-06-06 Univ Pennsylvania Vacunas novedosas contra el virus de zika.
CA3040123A1 (en) * 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
US11806393B2 (en) * 2017-02-10 2023-11-07 La Jolla Institute For Allergy And Immunology Flavivirus peptide sequences, epitopes, and methods and uses thereof
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
CA3081581A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
SG11202004863QA (en) 2017-11-30 2020-06-29 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
WO2019113285A2 (en) * 2017-12-06 2019-06-13 Emory University Zika vaccines and methods of use
US11738079B2 (en) 2018-07-23 2023-08-29 The University Of Adelaide Zika virus vaccine
BR112021008217A2 (pt) * 2018-10-31 2021-08-17 Icahn School Of Medicine At Mount Sinai anticorpos humanos que têm como alvo vírus zika ns1, polipeptídeos ns1 e seus usos
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
US20250269010A1 (en) * 2021-02-05 2025-08-28 St Pharm Co., Ltd. Novel nucleic acid molecule

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE471983T1 (de) * 1998-09-02 2010-07-15 Us Gov Health & Human Serv Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
EP2026839A4 (en) 2005-12-14 2009-04-01 Univ Oklahoma RNA VIRUS VACCINE AND METHODS
MX2010007461A (es) 2008-01-11 2010-10-20 VGX Pharmaceuticals LLC Nuevas vacunas contra multiples subtipos del virus del dengue.
AU2009313714B2 (en) 2008-11-17 2016-05-19 Inovio Pharmaceuticals, Inc. Antigens that elicit immune response against flavivirus and methods of using same
CA2771334A1 (en) * 2009-09-14 2011-03-17 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
CA3030893C (en) * 2009-11-02 2022-11-29 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
US8691961B1 (en) * 2009-11-09 2014-04-08 Integral Molecular, Inc. Flavivirus reporter virus and methods of making and using the same
WO2011115583A1 (en) 2010-03-19 2011-09-22 National University Of Singapore A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens
WO2011119716A2 (en) * 2010-03-24 2011-09-29 Research Development Foundation Flavivirus host range mutations and uses thereof
WO2012076715A1 (en) * 2010-12-09 2012-06-14 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
EA033467B1 (ru) * 2011-01-31 2019-10-31 Univ Pennsylvania Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
JP6215223B2 (ja) 2011-12-09 2017-10-18 アンスティテュ・パストゥール マルチプレックス免疫スクリーニングアッセイ
US9987347B2 (en) * 2013-03-15 2018-06-05 The Trustees Of The University Of Pennsylvania Vaccines against multiple subtypes of dengue virus
CA2992531C (en) 2015-07-16 2023-09-26 Bharat Biotech International Limited Vaccine compositions
WO2017015463A2 (en) * 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
EP3364950A4 (en) * 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
MX2018009917A (es) * 2016-02-17 2019-08-14 Curevac Ag Vacuna contra el virus del zika.
MX2018010291A (es) * 2016-02-25 2019-06-06 Univ Pennsylvania Vacunas novedosas contra el virus de zika.
EP4039272A1 (en) * 2016-07-18 2022-08-10 Variation Biotechnologies Inc. Vaccine compositions for treatment of zika virus
EP3515482A4 (en) * 2016-09-19 2020-09-30 The Wistar Institute Of Anatomy And Biology ASSOCIATION OF NEW ZIKA VIRUS VACCINES AND ANTI-DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST ZIKA VIRUS
MX2019008303A (es) * 2017-01-11 2019-12-02 Univ Pennsylvania Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika.
EP3412307A1 (en) * 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications

Also Published As

Publication number Publication date
JP2024096281A (ja) 2024-07-12
WO2017147458A1 (en) 2017-08-31
AU2021258056A1 (en) 2021-11-25
BR112018017307A2 (pt) 2019-01-08
US20210315987A1 (en) 2021-10-14
AU2017222644B2 (en) 2021-07-29
CN109152826B (zh) 2022-11-04
JP2022023241A (ja) 2022-02-07
EP3419660A1 (en) 2019-01-02
KR20190003471A (ko) 2019-01-09
AU2021258056B2 (en) 2024-04-04
JP7012365B2 (ja) 2022-03-04
JP2019506175A (ja) 2019-03-07
US11648303B2 (en) 2023-05-16
JP7555325B2 (ja) 2024-09-24
CN109152826A (zh) 2019-01-04
AU2024204641A1 (en) 2024-07-25
US20240115689A1 (en) 2024-04-11
EP3419660A4 (en) 2019-11-06
MX2023006203A (es) 2023-06-12
AU2017222644A1 (en) 2018-09-13
US12419945B2 (en) 2025-09-23
CN115927399A (zh) 2023-04-07
CA3015792A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
MX2018010291A (es) Vacunas novedosas contra el virus de zika.
MX2010007461A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
Liu Immunologic basis of vaccine vectors
CO2021004188A2 (es) Vacuna contra el virus de la peste porcina africana
CO2018005258A2 (es) Vacuna del virus herpes simple
CL2017000987A1 (es) Partículas tipo virus modificadas de cmv
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
MX2023012264A (es) Mejora del efecto de celulas t dise?adas por car por medio de vacunacion con acido nucleico.
EA201891415A8 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
CL2019000704A1 (es) Vectores de adenovirus canino.
WO2010044919A3 (en) Smallpox dna vaccine and the antigens therein that elicit an immune response
CO2017007105A2 (es) Nuevos virus de tilapia
EA201891460A1 (ru) Композиция дендритных клеток
EA201992282A1 (ru) Усовершенствованные вакцины против вируса папилломы человека и способы их применения
EA201891124A3 (ru) Новые мукозные адъюванты и системы доставки
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
RU2016116988A (ru) Вакцина против haemophilus parasuis серологического типа 4
MX2022007398A (es) Vacunas contra el virus de la fiebre porcina africana y métodos para usarlas.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
ECSP12012131A (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quiméricos
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
WO2015048796A3 (en) Mosaic hiv envelope immunogenic polypeptides
BR112014014390A2 (pt) levedura recombinante, seus usos, processo para vacinação, oligonucleotídeo, vetor de expressão, e método de produção de uma composição de vacina